CHUGAI PHARMAC.UNSP.ADR 2

Loading quotes...

Forecast

There is no analyst data available for this company.

News Go to news feed

There is currently no news available for this company. We are working on adding more providers to change this.

Historical dividends Dividends

All dividend metrics All metrics

In 2026, CHUGAI PHARMAC.UNSP.ADR 2 has already paid €0.57 in dividends. The last payout was in September.

Financials

In the last quarter, CHUGAI PHARMAC.UNSP.ADR 2 had revenue of €1.86B and net profit of €634.97M

(EUR)	June 2026	YoY
Revenue	1.86B	8.97%
Gross profit	1.3B	9.03%
Net profit	634.97M	10.78%
EBITDA	876.42M	2.57%

Fundamentals

Metric	Value
Market capitalization	€63.43B
Number of shares	3.29B
52-week high/low	€31.17 - €16.40
Dividend yield	3.01%
Dividends TTM	€0.57
Beta	0.56
P/E ratio	23.72
PEG ratio	1.24
P/B ratio	5.51
P/S ratio	8.33

Company profile

Chugai Pharmaceutical Co., Ltd., together with its subsidiaries, engages in the research, development, manufacturing, sale, importation, and exportation of pharmaceuticals in Japan and internationally. The company's products for oncology primarily include Avastin, Tecentriq, Perjeta, Alecensa, Herceptin, Kadcyla, Rituxan, Gazyva, and Xeloda; osteoporosis, including Actemra, Edirol, and Bonviva; renal diseases consist of Mircera and Oxarol; and neurology/other diseases comprise Hemlibra, CellCept, and Enspryng. It has various development product candidates in the areas of oncology, bone and joint diseases, autoimmune diseases, renal diseases, neurology, and other diseases. Chugai Pharmaceutical Co., Ltd. has strategic alliances with Roche Group; and collaboration and joint research with academia. The company was founded in 1925 and is headquartered in Tokyo, Japan. Chugai Pharmaceutical Co., Ltd. is a subsidiary of Roche Holding Ltd.

Name	CHUGAI PHARMAC.UNSP.ADR 2
CEO	Osamu Okuda
Headquarters	Tokyo, sh Japan
Website	chugai-pharm.co.jp
Sector	Health Care
Industry	Pharmaceuticals
IPO	08/03/2012
Employees	7,872